Navigate Fool.com
Will AVNR beat
the market?



Community Rating: 2 Stars: Unattractive

3.47 -0.13 (-3.61%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.61
Previous Close $3.60
Daily Range $3.46 - $3.64
52-Week Range $2.62 - $6.00
Market Cap $528.5M
P/E Ratio -7.06
Dividend (Yield) $0.00 (0.0%)
Volume 1,248,629
Average Daily Volume 2,118,693
Current FY EPS -$0.29

How do you think AVNR
will perform against the market?

Top AVNR Bull/Bear Pitches


peter1568 (0)
Submitted November 25, 2010

avnr is a takeover target for big business, has approved drug, little or no debt and enough money for its production and distribution, I believe that large company that already has spoken waiting for … More

2 Replies Reply Report this Post

maine2012 (0)
Submitted August 25, 2006

I FOOLISHLY choose this stock and based on a crazy madman and have watched it plummet ever since.

0 Replies Reply Report this Post

News & Commentary Rss Feed

Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014

A big mid-stage disappointment sent Avanir's (AVNR) shares tumbling, but the future may not be as bad as some fear.

Thursday's ETF Movers: ILF, XPH

Top Biotech Stocks Under $5 With Huge Potential Upside

Will Mallinckrodt's Xartemis Change How We Treat Pain?

Mallinckrodt's (MNK) pain killer drug Xartemis may give doctors a drug that's less likely to be abused than current options.

4 New Issues IPO Investors Need to Know About for This Week

IPOs continue to fly by thick and fast in the early days of 2014. Here are four worth keeping an eye on over the next few days.

Avanir Pharmaceuticals' Revenue Soars 62% on Strong Nuedexta Sales

Avanir's loss shrinks as higher sales of PBA drug Nuedexta counter a rise in R&D and marketing costs.

3 Companies Working on Parkinson's Treatments You Ought to Know About

Parkinson's may be tough-to-treat, but Chelsea (CHTP), Avanir (AVNR), and Prothena (PRTA) are hard at work developing new treatments.

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Biotech Week in Review

Avanir, Orexigen, XOMA, and Merrimack made biotech headlines last week.

Keep an Eye on AstraZeneca, Avanir, Bristol-Myers Squibb and VIVUS Today

4 Biotechs On the Move Today

See More AVNR News...






A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Website: http://www.avanir.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks